CHAPTER 1 - HEMOSTASIS PART 5 Flashcards
BLEEDING DISORDERS
- Superficial bleeding
- Deep tissue bleeding
Superficial bleeding -Ex:
epistaxis, petechiae, gingival bleeding
associated with platelet disorder or defect (either in function or in morphology) and with a vascular disorder
Superficial bleeding
caused by a defect in primary hemostasis
Superficial bleeding
Deep tissue bleeding -Ex.
hemarthrosis, hematomas
caused by a defect in secondary hemostasis (clotting or coagulation factors)
Deep tissue bleeding
QUALITATIVE PLÄTELET DISORDERS Manifested by
excessive bruising, superficial bleeding and prolonged BT.
External factors: acquired from a viral infection from an inflammation caused by lifestyle or others
- Acquired
Mild
- Acquired
Hereditary or inborn errors
- Congenital
characterized by 3 major platelet function (adhesion, aggregation, platelet/granule release)
- Congenital
- problem or defect with the interaction of platelet and blood vessel
Adhesion Defects (Platelet-vessel wall interaction)
BernardSoulier Syndrome
• Deficiency in
Gp Ib/IX complex
- complex responsible for adhesion
Gp Ib/IX and von Willebrand complex
BernardSoulier Syndrome
• Characterics:
large platelets and thrombocytopenia
BernardSoulier Syndrome
• Laboratory:
Prolonged Bleeding Time
No platelet count formed because the platelet cannot adhere to the bv/skin
BernardSoulier Syndrome
• Aggregation studies
a. Normal with:
b. Abnormal with:
Epinephrine, ADP, Collagen
Ristocetin
(in-vitro; collection of blood sample and induce aggregation using the ff. chemicals that are also found in the body that stimulates platelet aggregation and adhesion):
• Aggregation studies
BernardSoulier Syndrome
Treatment: cannot be corrected by adding [?]; no specific treatment; [?]–
normal plasma or cryoprecipitate
Desmosin acetate + recombinant factor Vila
used to arrest the bleeding if needed
Desmosin acetate + recombinant factor Vila
generate clot using tissue factors
Desmosin acetate + recombinant factor Vila
temporary treatment
Desmosin acetate + recombinant factor Vila
Transfusion of normal plasma will still continue bleeding; Platelet transfused will be worn out; Original plt will still have the defect of adhesion
BernardSoulier Syndrome
manifested in infancy or childhood
BernardSoulier Syndrome
BernardSoulier Syndrome signs and symtoms:
1) epistaxis, 2) gingival bleeding, and 3) ecchymosis
4 glycoproteins required to form Gp Ib/IX complex:
o Gp Iba – Chromosome 17
o Gp IbB – Chromosome 22
o Gp IbIX – Chromosome 3
o Gp V – Chromosome 3
: attaches thrombin and VWF to the injury site
o Gp Iba – Chromosome 17
: major complex for adhesion but enhanced with Gp V
Gp Ib/IX
enhances the fx of these receptors to complete the adhesion complex (Gp Ib/IX and von Willebrand complex)
Gp V
: complex is present, but nonfunctional/defective
Pseudo Bernard-Soulier Syndrome
von Willebrand disease
• (Autosomal) deficiency in
plasma VIII:vWF (Factor VIII complex)
cannot exist alone like VIII
vWF
– in complex with a multimerprotein, w/c is vWF
Factor VIII complex
• Same aggregation test result with Bernard-Soulier
von Willebrand disease
von Willebrand disease
• Common sign/Characterics:
mucocutaneous bleeding
von Willebrand disease
• Laboratory:
Platelet count and morphology are generally NORMAL
von Willebrand disease
• Aggregation studies:
a. Normal with:
b. Abnormal with:
Epinephrine, ADP, Collagen
Ristocetin
von Willebrand disease
• Diagnosis:
Standard WWD test panel tests:
1. quantitative VWF test (VWF: Ag assay)
2. VWF activity test/ VWF:RCo assay (qualitative; ability of WWF to bind to platelets)
3. factor VIll activity assay
von Willebrand disease
• Treatment:
Cryoprecipitate; Desmopressin acetate (1-desamino-8-D arginine vasopressin/ DDAVP)
Cryoprecipitate contains:
F I (fibrinogen), F VIII, F XIII, VWF, Fibronectin
: adhesive ligand (causes the production of clot
V Fibronectin
promotes spreading of plt and adhesion of wbc to avoid infection
Fibronectin
: causes the release of VWF antigen in the linings of bv
Desmopressin acetate
: carries F VIII complex
VWF antigen
Partial quantitative deficiency of von Willebrand factor (VWF); approximately 75%
1
Qualitative deficiency of VWF
2
weight multimers (the WWF is more susceptible to proteolysis by ADAMTS-13)
2A
Increased affinity for platelet glycoprotein Ib/IXN
2B
Decreased platelet receptor binding
2M
(Normandy Variant) Impaired factor VIII binding site
2N